The latest episode of QuidelOrtho Science Bytes explores how the overdose crisis has evolved from 2025 to 2026 and what these changes mean for laboratories and healthcare providers.Host Josh Casey is joined by Vonda McAllister, Director of Global Product Management at QuidelOrtho, to discuss emerging drug trends, new ADLM guidance for toxicology testing and the growing challenges posed by counterfeit medications, polysubstance use and novel synthetic opioids.This episode reinforces an important message: as the drug landscape continues to change, healthcare organizations must adapt testing strategies, strengthen collaboration and ensure clinicians have timely, actionable information to support patient care. About Our Speaker: Vonda McAllister, director of global product management for QuidelOrthoVonda's diagnostic experience spans from R&D and program management to marketing. Now a member of the Point of Care business unit, she previously managed the Triage™ portfolio of assays and the clinical labs team for North America. Vonda is currently focused on supporting the global regions with our PlGF tests, that is, placental growth factor, and toxicology assays, as well as expanding the Triage toxicology and women's health testing portfolio. She also serves as global leadership co-chair for the QuidelOrtho Women's Leadership Network.